Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with symptomatic peripheral artery disease (PAD) and Type 2 diabetes in the first ...

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with symptomatic peripheral artery disease (PAD) and Type 2 diabetes in the first ...

At week 52, the estimated median ratio to baseline in maximum walking distance was 1.21 in the semaglutide group compared to 1.08 in the placebo group.

Session ID: 2025-08-17:f7ea570de1931b201e2bf810 Player Element ID: vjs_video_3 ...

For the treatment policy estimand, the mean change in the 6-minute walk distance at week 52 was 21.5 m in the semaglutide group and 1.2 m in the placebo group (estimated difference, 20.3 m; 95% CI ...

Semaglutide 2.4 mg outperformed placebo in MASH resolution (62.9% vs. 34.1%) and improvement in fibrosis (37% vs. 22.5%) at 72 weeks. Safety profile was consistent with previous phase 2 trials.

Tirzepatide (Zepbound; Eli Lilly) and semaglutide (Wegovy and Ozempic; Novo Nordisk), popular weight loss drugs that show significant health benefits for reduced rates of obesity, diabetes, and ...